| Giving IV and oral amiodarone perioperatively for the prevention of postoperative atrial fibrillation in patients undergoing coronary artery bypass surgery: the GAP study. | |
| | |
MedLine Citation:
|
PMID: 15364747 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSES: We studied the use of perioperative IV and oral administration of amiodarone for the prevention of postoperative atrial fibrillation in patients undergoing coronary artery bypass graft surgery (CABG). BACKGROUND: In the United States, > 500,000 patients undergo CABG each year. Numerous studies to date have suggested that postoperative atrial fibrillation occurs in 30 to 50% of patients, leading to significant morbidity, including hypotension, heart failure, thromboembolic complications, prolonged hospital stay, and increased hospital costs. The objective of this study was to assess the use of IV amiodarone in combination with oral amiodarone to reduce the incidence of postoperative atrial fibrillation. METHOD: From January 1999 to October 1999, 51 patients scheduled for CABG were randomly selected for participation in the amiodarone administration trial. IV amiodarone, 0.73 mg/min, was administered on call to the operating room for 48 h, followed by oral amiodarone, 400 mg q12h, for the next 3 days. The amiodarone group was case-control matched to the incidence of postoperative atrial fibrillation in 92 patients undergoing CABG using conventional medical therapy during the same period. The primary end point of this study was the incidence of postoperative atrial fibrillation, length of hospital stay, and hospital costs, compared to the control group undergoing CABG during the same time. RESULTS: Atrial fibrillation occurred in 3 of 51 patients (5.88%) in the amiodarone group, compared to 24 of 92 patients (26.08%) in the control group. Length of hospital stay in the amiodarone group was less than in the control group (5.3 days vs 6.7 days), with a trend toward decrease in hospital costs. CONCLUSION: The administration of IV amiodarone in conjunction with oral amiodarone for a total dose of 4,500 mg over 5 days appears to be a hemodynamically well-tolerated, safe, and effective treatment in decreasing the incidence of postoperative atrial fibrillation, shortening length of stay, and a trend toward lowering hospital costs, even in patients with significantly reduced left ventricular function (< 30%). A large multicenter study using IV and oral amiodarone should be pursued prior to deciding whether its use should become standard therapy in all patients undergoing CABG in order to decrease the incidence of postoperative atrial fibrillation. |
| | |
Authors:
|
Joshua Kerstein; Ajay Soodan; Mehdi Qamar; Mazhar Majid; Edgar Lichstein; Gerald Hollander; Jacob Shani |
Related Documents
:
|
8775337 - Long-term prevention of atrial fibrillation after coronary artery bypass surgery: compa... 11289397 - Sustained ventricular tachycardia in children after repair of congenital heart disease. 2184287 - Intravenous amiodarone bolus versus oral quinidine for atrial flutter and fibrillation ... 19422577 - Primary prevention implantation of cardioverter defibrillator without defibrillation th... 1350407 - A double-blind comparison of acitretin and etretinate in the treatment of darier's dise... 18206597 - Importance of the new radiographic sign of fecal loading in the cecum in the presence o... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Chest Volume: 126 ISSN: 0012-3692 ISO Abbreviation: Chest Publication Date: 2004 Sep |
Date Detail:
|
Created Date: 2004-09-14 Completed Date: 2004-11-02 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0231335 Medline TA: Chest Country: United States |
Other Details:
|
Languages: eng Pagination: 716-24 Citation Subset: AIM; IM |
Affiliation:
|
Maimonides Medical Center, 953 49th St, Brooklyn, NY 11219, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Aged Amiodarone / administration & dosage*, adverse effects, economics Anti-Arrhythmia Agents / administration & dosage*, adverse effects, economics Atrial Fibrillation / economics, prevention & control* Case-Control Studies Coronary Artery Bypass* / economics Coronary Artery Disease / economics, surgery* Cost Savings / statistics & numerical data Dose-Response Relationship, Drug Drug Administration Schedule Electrocardiography / drug effects Female Hemodynamics / drug effects Hospital Charges / statistics & numerical data Humans Infusions, Intravenous Length of Stay / economics Male Middle Aged Myocardial Reperfusion Injury / prevention & control* Postoperative Complications / economics, prevention & control* Premedication / economics |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Arrhythmia Agents; 1951-25-3/Amiodarone |
| Comments/Corrections | |
Comment In:
|
Chest. 2004 Sep;126(3):662-4
[PMID:
15364735
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mitral valve repair in patients with low left ventricular ejection fractions: early and late results...
Next Document: Long-term survival after videothoracoscopic lobectomy for stage I lung cancer.